EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population

Arthur Shiyovich iD, Adam N Berman iD, Stephanie A Besser, David W Biery, Daniel M Huck, Brittany Weber iD, Christopher Cannon, James L Januzzi, John N Booth, Khurram Nasir iD, Marcelo F Di Carli, J Antonio G López und 3 weitere

European Heart Journal Open · 03.07.2023 · 3 (4)

DOI: 10.1093/ehjopen/oead077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 27.08.2023. Verfasst von Arthur Shiyovich und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The ongoing Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction [OCEAN(a)]-Outcomes trial is evaluating whether Lp(a) lowering can reduce the incidence of cardiovascular events among patients with prior myocardial infarction (MI) or percutaneous coronary intervention (PCI) and elevated Lp(a) (≥200 nmol/L). The purpose of this study is to evaluate the association of elevated Lp(a) with cardiovascular outcomes in an observational cohort resembling the OCEAN(a)-Outcomes trial main enrolment criteria. Methods and results This study included patients aged 18–85 years with Lp(a) measured as part of their clinical care between 2000 and 2019. While patients were required to have a history of MI, or PCI, those with severe kidney dysfunction or a malignant neoplasm were excluded. Elevated Lp(a) was defined as ≥200 nmol/L consistent with the OCEAN(a)-Outcomes trial. The primary outcome was a composite of coronary heart disease death, MI, or coronary revascularization. Natural language processing algorithms, billing and ICD codes, and laboratory data were employed to identify outcomes and covariates. A total of 3142 patients met the eligibility criteria, the median age was 61 (IQR: 52–73) years, 28.6% were women, and 12.3% had elevated Lp(a). Over a median follow-up of 12.2 years (IQR: 6.2–14.3), the primary composite outcome occurred more frequently in patients with versus without elevated Lp(a) [46.0 vs. 38.0%, unadjHR = 1.30 (95% CI: 1.09–1.53), P = 0.003]. Following adjustment for measured confounders, elevated Lp(a) remained independently associated with the primary outcome [adjHR = 1.33 (95% CI: 1.12–1.58), P = 0.001].

Conclusion

In an observational cohort resembling the main OCEAN(a)-Outcomes Trial enrolment criteria, patients with an Lp(a) ≥200 nmol/L had a higher risk of cardiovascular outcomes.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular outcomesCoronary artery diseaseLipoprotein(a)Olpasiran

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Cardiology Division, Massachusetts General Hospital, Harvard Medical School, and Baim Institute for Clinical Research, Boston, MA 02115, USA.
  • Center for Observational Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Department of Cardiovascular Medicine, Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA.
  • Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA.

ORCID-Profile: Arthur Shiyovich, Adam N Berman, Brittany Weber, Khurram Nasir, Deepak L Bhatt

Zitieren

APA

Shiyovich, A., Berman, A. N., Besser, S. A., Biery, D. W., Huck, D. M., Weber, B., Cannon, C., Januzzi, J. L., Booth, J. N., Nasir, K., Di Carli, M. F., López, J. A. G., Kent, S. T., Bhatt, D. L., & Blankstein, R. (2023). Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. European Heart Journal Open, 3(4). https://doi.org/10.1093/ehjopen/oead077

Vancouver

Shiyovich A, Berman AN, Besser SA, Biery DW, Huck DM, Weber B, et al. Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. European Heart Journal Open. 2023;3(4). doi:10.1093/ehjopen/oead077

BibTeX
@article{Shiyovich2023,
  author = {Shiyovich, Arthur and Berman, Adam N and Besser, Stephanie A and Biery, David W and Huck, Daniel M and Weber, Brittany and Cannon, Christopher and Januzzi, James L and Booth, John N and Nasir, Khurram and Di Carli, Marcelo F and López, J Antonio G and Kent, Shia T and Bhatt, Deepak L and Blankstein, Ron},
  title = {Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population},
  journal = {European Heart Journal Open},
  year = {2023},
  volume = {3},
  number = {4},
  doi = {10.1093/ehjopen/oead077}
}
Kostenlos starten →